- Home
- VSTM vs PHAT Comparison
VSTM vs PHAT Comparison
Compare VSTM & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- PHAT
- Stock Information
- Founded
- VSTM 2010
- PHAT 2018
- Country
- VSTM United States
- PHAT United States
- Employees
- VSTM N/A
- PHAT N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- VSTM Health Care
- PHAT Health Care
- Exchange
- VSTM Nasdaq
- PHAT Nasdaq
- Market Cap
- VSTM 313.1M
- PHAT 339.8M
- IPO Year
- VSTM 2012
- PHAT 2019
- Fundamental
- Price
- VSTM $5.74
- PHAT $4.03
- Analyst Decision
- VSTM Strong Buy
- PHAT Strong Buy
- Analyst Count
- VSTM 9
- PHAT 5
- Target Price
- VSTM $13.13
- PHAT $22.50
- AVG Volume (30 Days)
- VSTM 902.1K
- PHAT 1.2M
- Earning Date
- VSTM 05-08-2025
- PHAT 05-08-2025
- Dividend Yield
- VSTM N/A
- PHAT N/A
- EPS Growth
- VSTM N/A
- PHAT N/A
- EPS
- VSTM N/A
- PHAT N/A
- Revenue
- VSTM $10,000,000.00
- PHAT $55,252,000.00
- Revenue This Year
- VSTM $7.68
- PHAT $202.23
- Revenue Next Year
- VSTM $605.06
- PHAT $113.81
- P/E Ratio
- VSTM N/A
- PHAT N/A
- Revenue Growth
- VSTM N/A
- PHAT 8001.47
- 52 Week Low
- VSTM $2.10
- PHAT $3.81
- 52 Week High
- VSTM $13.52
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- VSTM 51.60
- PHAT 38.04
- Support Level
- VSTM $4.69
- PHAT $3.81
- Resistance Level
- VSTM $5.12
- PHAT $5.09
- Average True Range (ATR)
- VSTM 0.55
- PHAT 0.68
- MACD
- VSTM -0.02
- PHAT -0.10
- Stochastic Oscillator
- VSTM 70.35
- PHAT 7.72
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.